2020-043 – SHP2 Inhibitors for Cancer Therapy

SHP2 is a protein phosphatase that regulates the RAS pathway that plays a central role in cancer, especially pancreatic, lung, breast, leukemia, melanoma, and ovarian cancer. SHP2 inhibitors have demonstrated high activity in preclinical studies. KSU researchers have discovered new SHP2 inhibitors that have demonstrated significant activity against multiple cancer cell lines. These SHP2 inhibitors are chemically different from other SHP2 inhibitors described in the research and patent literature. They show activity against non-small cell lung cancer, glioblastoma, renal cancer, breast cancer cell lines with GI50 = 1-4 µM. They also show specific cytotoxic activity against melanoma cell lines at 10 µM. Cell cytotoxicity assays were performed by the National Cancer Institute. Caronda Moore caronda@ksu.edu 785-532-1366

Related Blog

Smart, interactive desk

Get ready to take your space management game to the next level with the University of Glasgow’s innovative project! By combining the

Mechanical Hamstring™

University of Delaware Technology Overview This device was created to allow athletes who suffer a hamstring strain to return to the field

Join Our Newsletter

                                                   Receive Innovation Updates, New Listing Highlights And More